Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). This includes both metallic and bioresorbable drug-eluting stents and related clinical trial data.

Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018

May 31, 2018 — Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-...

OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018

May 29, 2018 – Investigators recently unveiled...

Medtronic Begins Bifurcation Cohort of U.S. RESOLUTE ONYX Study
News | Stents Bifurcation | May 29, 2018

May 29, 2018 – Medtronic plc announced the initiation of a U.S....

Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018

May 25, 2018 — Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience...

Videos | ACC | March 21, 2018

DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at the 2018...

Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018

February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S. Food and Drug...

Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018

February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently...

Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial
News | Antiplatelet and Anticoagulation Therapies | February 13, 2018

February 13, 2018 — Abbott announced the first patient has been enrolled in a...

12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018

February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s...

Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018

January 25, 2018 – Data presented at the Biotronik-sponsored...

Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018

January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling...

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell

There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or...

Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017

December 13, 2017 — Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug...

The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017

November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting,...

Overlay Init